-
公开(公告)号：US20180303815A1
公开(公告)日：2018-10-25
申请号：US15767914
申请日：2016-11-03
发明人： Mark Merchant , Deepak Sampath , Marina Konopleva , Lina Han
IPC分类号： A61K31/4523 , A61P35/02
CPC分类号： A61K31/4523 , A61K31/496 , A61K45/06 , A61K2300/00 , A61P35/02
摘要： The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.
-
公开(公告)号：US20210169865A1
公开(公告)日：2021-06-10
申请号：US17178609
申请日：2021-02-18
发明人： Mark Merchant , Deepak Sampath , Marina Konopleva , Lina Han
IPC分类号： A61K31/4523 , A61K45/06 , A61K31/496 , A61P35/02
摘要： The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.
-
公开(公告)号：US10959993B2
公开(公告)日：2021-03-30
申请号：US15767914
申请日：2016-11-03
发明人： Mark Merchant , Deepak Sampath , Marina Konopleva , Lina Han
IPC分类号： A61K31/5365 , A61K31/497 , A61K31/4523 , A61K45/06 , A61K31/496 , A61P35/02
摘要： The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.
-
公开(公告)号：US20240000776A1
公开(公告)日：2024-01-04
申请号：US18463252
申请日：2023-09-07
发明人： Deepak Sampath , Christian Klein , Wayne John Fairbrother , Sari L. Heitner Enschede , Rod A. Humerickhouse , Andrew W. Roberts , John F. Seymour
IPC分类号： A61K31/496 , A61K31/02 , A61K31/04 , A61K31/10 , A61K31/18 , A61K31/33 , A61K31/436 , A61K31/437 , A61K31/4375 , A61K31/45 , A61K31/505 , A61K31/63 , A61K39/395
CPC分类号： A61K31/496 , A61K31/02 , A61K31/04 , A61K31/10 , A61K31/18 , A61K31/33 , A61K31/436 , A61K31/437 , A61K31/4375 , A61K31/45 , A61K31/505 , A61K31/63 , A61K39/39558 , A61K2039/545
摘要： The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
-
公开(公告)号：US11110087B2
公开(公告)日：2021-09-07
申请号：US17187468
申请日：2021-02-26
发明人： Deepak Sampath , Christian Klein , Wayne John Fairbrother , Sari L. Heitner Enschede , Rod A. Humerickhouse , Andrew W. Roberts , John F. Seymour
IPC分类号： A61K31/496 , A61P35/02 , A61P35/00 , A61K39/395
摘要： The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
-
公开(公告)号：US20210177838A1
公开(公告)日：2021-06-17
申请号：US17187468
申请日：2021-02-26
发明人： Deepak Sampath , Christian Klein , Wayne John Fairbrother , Sari L. Heitner Enschede , Rod A. Humerickhouse , Andrew W. Roberts , John F. Seymour
IPC分类号： A61K31/496
摘要： The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
-
7.发明申请公开(公告)号：US20180280505A1
公开(公告)日：2018-10-04
申请号：US15885040
申请日：2018-01-31
申请人： Genentech, Inc.
发明人： Sairy Hernandez , Ira Mellman , Jing Qing , Deepak Sampath
IPC分类号： A61K39/395 , C07K16/28
摘要： Compositions and methods for enhancing an immune response and treating cancer are provided. Compositions comprise PD-1 axis antagonists and HPK1 antagonists. PD-1 axis antagonists include PD-1 antagonists, PD-L1 antagonists, and PD-L2 antagonists. PD-1 axis antagonists can inhibit the binding of PD-L1 and/or PD-L2 to PD-1. HPK1 antagonists include compounds that inhibit the serine/threonine kinase activity of HPK1. Methods for enhancing an immune response or treating cancer comprise administering a PD-1 axis antagonist and a HPK1 antagonist, sequentially or simultaneously, to a subject in need thereof.
-
8.发明申请COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE 有权AKT抑制剂化合物和ERLOTINIB的组合及其使用方法公开(公告)号：US20160051550A1
公开(公告)日：2016-02-25
申请号：US14836827
申请日：2015-08-26
申请人： GENENTECH, INC.
发明人： Michelle Nannini , Deepak Sampath
IPC分类号： A61K31/517
CPC分类号： A61K31/517 , A61K31/138 , A61K31/282 , A61K31/337 , A61K31/4166 , A61K31/4188 , A61K31/436 , A61K31/437 , A61K31/4745 , A61K31/495 , A61K31/496 , A61K31/513 , A61K31/519 , A61K31/555 , A61K31/58 , A61K31/704 , A61K31/7068 , A61K39/3955 , A61K2039/505 , C07D239/70 , C07D403/12 , C07K16/40 , A61K2300/00
摘要： The invention provides A combination of, a) a compound of Formula Ia: or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
摘要翻译： 本发明提供以下组合：a）式Ia化合物或其药学上可接受的盐; 和b）厄洛替尼或其药学上可接受的盐，用于预防或治疗过度增殖性疾病如癌症的治疗。
-
公开(公告)号：US20220008413A1
公开(公告)日：2022-01-13
申请号：US17193795
申请日：2021-03-05
IPC分类号： A61K31/496
摘要： The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
-
公开(公告)号：US20210213130A1
公开(公告)日：2021-07-15
申请号：US17129096
申请日：2020-12-21
申请人： GENENTECH, INC.
IPC分类号： A61K39/395 , C07K16/32 , G01N33/574 , A61K47/68 , A61K31/635 , A61K45/06 , A61P35/00 , A61K31/496
摘要： The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.
-
-
-
-
-
-
-
-
-
搜索结果
39 条记录 (耗时 0.033 秒)
